Lab
American Specialty Laboratory , INC
American Specialty Laboratory , INC was paid $2.21M by Medicaid between Jan 2018 and Nov 2024, across 12 billing codes. Its largest line is 88325, — 40% of everything it billed.
33Billing provider infoAMERICAN SPECIALTY LABORATORY , INC
CHATSWORTH, CA 91311
CHATSWORTH, CA 91311
33aNPI1316200504assigned 06/21/2012
33bProvider typeClinical Medical Laboratory
28Total paid$2.21M
24GClaims74,941
24DCodes billed12
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#143 of 561
Median peer was paid$222K
This provider vs. median9.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 308 | $2K | |
| 2019 | 1,479 | $78K | |
| 2020 | 2,316 | $113K | |
| 2021 | 22,955 | $535K | |
| 2022 | 26,152 | $765K | |
| 2023 | 12,591 | $448K | |
| 2024incomplete | 9,140 | $264K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88325 | 40% | 15,014 | 10,188 | $890K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 21% | 11,459 | 8,801 | $460K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 14% | 10,000 | 7,763 | $318K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 6.3% | 7,346 | 6,301 | $140K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 5.1% | 10,671 | 8,170 | $113K |
| 88361 | 5.0% | 1,513 | 1,027 | $109K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.1% | 9,512 | 7,318 | $92K |
| 88307 | 2.1% | 2,199 | 1,882 | $45K | |
| 88312 | 1.2% | 1,201 | 1,065 | $27K | |
| 88300 | <1% | 5,973 | 5,868 | $11K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 33 | 26 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 20 | 17 | $945.96 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialASKAR, NAGHAM (DIRECTOR OF OPERATION)